XML 33 R21.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting
9 Months Ended
Sep. 30, 2025
Segment Reporting  
Segment Reporting

14. Segment Reporting

The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company’s chief operating decision maker (“CODM”). The Company’s CODM is its Chief Executive Officer, who reviews financial information on an aggregate basis for purposes of assessing performance, making operating decisions, allocating resources and evaluating financial performance. The Company maintains 99.5% of its $12.6 million property and equipment, net within the United States.

The following table includes certain segment information for the periods presented (in thousands):

Three Months Ended September 30, 

Nine Months Ended September 30, 

2025

2024

2025

2024

Grant and award revenue

$

1,159

$

2,973

$

3,819

$

3,939

Operating expenses

Research and development expenses:

AP-PA02: Non-Cystic Fibrosis Bronchiectasis

190

1,858

(98)

5,459

AP-PA02: Cystic Fibrosis

-

-

25

235

AP-SA02: Bacteremia

404

1,618

2,067

2,752

AP-SA02: Prosthetic Joint Infection

-

-

2

8

Expenses not allocated by projects*

545

726

1,657

1,903

Total external research and development expenses

1,139

4,202

3,653

10,357

Research and development personnel expenses

2,287

2,874

6,893

8,296

Other research and development expenses

2,398

2,409

7,101

7,322

Total research and development expenses

5,824

9,485

17,647

25,975

General and administrative expenses:

General and administrative personnel expenses

1,141

1,273

3,733

3,778

Other general and administrative expenses

1,970

1,971

5,250

6,083

Total general and administrative expenses

3,111

3,244

8,983

9,861

Total operating expenses

8,935

12,729

26,630

35,836

Operating loss

(7,776)

(9,756)

(22,811)

(31,897)

Other income (expense), net

(18,899)

4,275

(26,690)

10,381

Net loss

$

(26,675)

$

(5,481)

$

(49,501)

$

(21,516)